IMB Dx, Inc. (KOSDAQ:461030)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,135.00
-110.00 (-2.59%)
Jun 10, 2026, 3:30 PM KST
Market Cap57.96B -53.3%
Revenue (ttm)5.60B +59.6%
Net Income-8.41B
EPS-599.13
Shares Out 14.02M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume26,705
Open4,100.00
Previous Close4,245.00
Day's Range4,025.00 - 4,270.00
52-Week Range3,790.00 - 12,990.00
Beta0.35
Analystsn/a
Price Targetn/a
Earnings Daten/a

About IMB Dx

IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; AlphaLiquid HRR for diagnostics of targeted therapies, utilizing liquid biopsy profiling technology; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 461030
Full Company Profile

Financial Performance

In 2025, IMB Dx's revenue was 5.33 billion, an increase of 56.40% compared to the previous year's 3.41 billion. Losses were -7.93 billion, -17.15% less than in 2024.

Financial Statements